ArcherDX

Boulder, United States Founded: 2013 • Age: 13 yrs Acquired By Invitae
Molecular cancer diagnostic products are developed using patented AMP technology.
Annual revenue - Latest available
Total funding $152.6M 3 rounds
Employees 429 Tracked headcount
Investors 10 Known backers
Products - Services tracked
Competitors 9 Brand Intelligence

About ArcherDX

ArcherDX is a company based in Boulder (United States) founded in 2013 by John Iafrate and Long Phi Le was acquired by Invitae in June 2020. ArcherDX has raised $152.6 million across 3 funding rounds from investors including Invitae, Driehaus and Perceptive Advisors. The company has 429 employees as of December 31, 2022. ArcherDX has completed 1 acquisition, including Baby Genes. ArcherDX operates in a competitive market with competitors including Guardant Health, Natera, Foundation Medicine, Prenetics and Veracyte, among others.

  • Headquarter Boulder, United States
  • Employees 429 as on 31 Dec, 2022
  • Founders John Iafrate, Long Phi Le
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Archerdx, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $152.6 M (USD)

    in 3 rounds

  • Latest Funding Round
    $55 M (USD), Series C

    Dec 17, 2019

  • Investors
    Invitae

    & 9 more

  • Employee Count
    429

    as on Dec 31, 2022

  • Investments & Acquisitions
  • Acquired by
    Invitae

    (Jun 22, 2020)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

People of ArcherDX

Headcount 50-200
Employee Profiles 18
Board Members and Advisors 5
Employee Profiles
People
Young Pham
CloudLIMS Validation Project Lead
People
Josh Stahl
COO & Chief Scientific Officer
People
Ben Carver
General Counsel
People
Ryan Walters
EVP of Research & Development

Unlock access to complete

Funding Insights of ArcherDX

ArcherDX has successfully raised a total of $152.6M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $55 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in ArcherDX

ArcherDX has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Invitae, Driehaus and Perceptive Advisors.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Locked Locked Locked
PE firm investing in the US
Locked Locked Locked
Venture capital is offered by Boulder Ventures for innovative companies.
Locked Locked Locked
Premium access

Investor details for ArcherDX

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by ArcherDX

ArcherDX has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Baby Genes.

Investments
Premium access

Investment portfolio details for ArcherDX

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Genomic diagnostic solutions for neonates and carrier testing are provided.
Locked Locked 2013 Locked
Premium access

Complete acquisition details for ArcherDX

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - ArcherDX

Premium access

Detailed financials for ArcherDX

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Archerdx Comparisons

ArcherDX Primary company
Description
Molecular cancer diagnostic products are developed using pat...
Location
Boulder, United States
Founded Year
2013
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
429
As of 2022
Premium access

Peer comparison for ArcherDX

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of ArcherDX

ArcherDX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Foundation Medicine, Prenetics and Veracyte, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Digital sequencing technology for cancer detection is developed.
Locked Locked Locked
Developer of cell-free DNA testing for oncology, women’s health, and organ health
Locked Locked Locked
Genomics-based diagnostic tests for cancer are provided.
Locked Locked Locked
Health risks are identified through online genetic and diagnostic testing.
Locked Locked Locked
Genomics-based diagnostic tests for cancer are developed.
Premium access

Detailed competitors of ArcherDX

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Archerdx

Premium access

Complete news archive for ArcherDX

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about ArcherDX

ArcherDX was founded in 2013 and raised its 1st funding round 5 years after it was founded.

ArcherDX is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.

ArcherDX is a funded company, having raised a total of $152.6M across 3 funding rounds to date.

As of Dec 31, 2022, the latest employee count at ArcherDX is 429.

ArcherDX was founded in 2013 in Boulder, United States, within the biotechnology sector. Patented Anchored Multiplex PCR (AMP) technology is employed to create in-vitro diagnostics and Personalized Cancer Monitoring products for identifying solid tumor biomarkers. Operations focus on molecular diagnostics for oncology, with a product pipeline that includes ArcherMET, NTRK CDx, and Fusion Plex.

ArcherDX's top competitors include Guardant Health, Exact Sciences and Foundation Medicine.

ArcherDX has made 1 acquisition, including Baby Genes.

ArcherDX has 10 investors. Key investors include Invitae, Driehaus, Perceptive Advisors, ArrowMark Partners, and Soleus Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available